Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025)

Inhibikase Therapeutics (IKT) reported Capital Expenditures of $13399.0 for Q1 2025, down 93.31% quarter-over-quarter from $200166.0 in Q3 2022.

Inhibikase Therapeutics (IKT) Capital Expenditures (2022 - 2025) Analysis & Trends

Inhibikase Therapeutics (IKT) has 2 years of Capital Expenditures data on file, last reported at $13399.0 in Q1 2025.

Capital Expenditures for Q1 2025 came in at $13399.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $13399.0 (changed N/A YoY), and the FY2025 annual result was $13399.0, changed N/A from the prior year.
Capital Expenditures fell to $13399.0 in Q1 2025 per IKT's latest filing, from $200166.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $200166.0 in Q3 2022 and troughed at $13399.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	133.40 Mn
9	Abivax	91.71 Bn	91.71 Bn	-	-63,220.27
10	Inhibikase Therapeutics	285.17 Mn	114.80 Mn	-	-

Download Data